OCUGEN, INC. Gain (Loss) on Extinguishment of Debt
OCUGEN, INC. (OCGN) reported Gain (Loss) on Extinguishment of Debt of -$2.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-06
- OCUGEN, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was -$2.38M.
- OCUGEN, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- OCUGEN, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was $0.00.
- OCUGEN, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-09-30 was $0.00.
- OCUGEN, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- OCUGEN, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $426.00K.
- OCUGEN, INC. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
- OCUGEN, INC. gain (loss) on extinguishment of debt for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.38M 10-Q · filed 2026-08-06 | -$2.38M 10-Q · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $426.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $426.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $426.00K 10-Q · filed 2022-08-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $1.54M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |